Loading the company…
Loading the company…
㈜이든파마
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Chungbuk, founded in 2013. Industry: Bio & Pharma. Revenue for 2025 was ₩129.5bn. It has 27 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2025-09-26 · newest first
본 발명은 철갑상어 어백으로부터의 피디알엔 추출 방법을 개시한다. 본 발명의 방법은 (a) 철갑상어 어백 시료를 준비하는 단계, (b) 그 철갑상어 어백 시료의 세포를 파쇄하거나 용해하여 세포 파쇄 또는 용해액을 얻는 단계, (c) 그 세포 파쇄 또는 용해액에 단백분해효소 K를 처리하여 세포 파쇄 또는 용해액 중의 단백질을 분해하는 단계, (d) 단백분해효소 K가 처리된 세포 파쇄 또는 용해액 중의 단백질이나 단백질 분해물을 침전시켜 피디알엔인 포함된 상층액을 회수하는 단계 및 (e) 회수한 상층액에 알콜을 처리하여 피디알엔을 침전시켜 회수하는 단계를 포함함으로써 높은 수율로 피디알엔을 추출할 수 있다.
본 발명은 Hs68 피부 섬유아세포에서 콜라겐의 생성을 촉진하고 MMP-1 발현을 감소시키며, C2C12 근원세포의 스크래치 영역을 회복하는 활성을 가진, 소 양수 유래 엑소좀을 이용한 이용한 피부 주름 개선 및 피부 재생용 조성물을 개시한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 115.3 | 129.5 |
| Cost of sales | 33.8 | 37.3 |
| Gross profit (loss) | 81.5 | 92.2 |
| Selling, general and administrative expenses | 76.6 | 86.7 |
| Operating income (loss) | 4.9 | 5.5 |
| Non-operating income | 0.1 | 0.2 |
| Other gains | 0.0 | 0.1 |
| Finance income | 0.1 | 0.1 |
| Non-operating expenses | 0.1 | 0.2 |
| Other losses | 0.0 | 0.1 |
| Finance costs | 0.1 | 0.1 |
| Profit (loss) before tax | 4.9 | 5.5 |
| Income tax expense | 0.8 | 0.4 |
| Net income (loss) | 4.1 | 5.2 |
Revenue ₩129.5bn, up 12.3% YoY.
Operating margin 4.2% (prior 4.2%).
Net income ₩5.2bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05